Transcript MAT and Treatment Court

Pharmacotherapy of
Substance Use Disorders
Dr. John Brooklyn
Associate Clinical Professor of Family Medicine and Psychiatry
University of Vermont
Vt Opioid History
• 1840-Heavy reliance on alcohol as drug of choice. Homemade stills were
commonly used as was cider making
• 1850 Vt enacted Prohibition against alcohol. Dram laws came about
• 1860’s Post Civil War Morphine became available for soldiers with “military
disease”
• 1870-1890 Widespread use of opium containing products-patent medicines
from England, paregoric, tinctures of opium, heroin, morphine products.
Taken with a dram of alcohol for ingestion.
• Led to widespread abuse, demise and death as doses were not regulated.
• Boston had regularly received shipments of opium from Turkey destined for
VT
Vt Opioid History
• 1890-1900 Abuse of opioids was so extensive that NH and Mass
enacted laws to ban the export of opium containing products from VT
into their states. Physicians, druggists and apothecaries and general
stores dispensed opium products. 3 major manufacturers in the State
• 1900 Vt Medical Society speech by Dr. A.P. Grinnell indicated that
based on an incomplete survey he performed of all of the above
purveyors, 3,300,000 doses of opium were dispensed monthlyenough for 1 ½ doses for every man and woman above 21 a day for a
year or ½ dose for every Vermonter and he estimated that this was
underreported by a factor of 5.
Vt Opioid History
• 1906 Pure Food and Drug Act required labeling of patent medicines with opium, coca,
cannabis, alcohol, and other intoxicants
• As of 1911, an estimated one U.S. citizen in 400 (0.25%) was addicted to some form of
opium and were mostly women who were prescribed and dispensed legal opiates by
physicians and pharmacist for “female problems” (probably pain at menstruation) or
white men and Chinese at the opium dens.
• 1914 Harrison Act was passed regulating the marketing of opiates.
• A clause applying to doctors allowed distribution "in the course of his professional
practice only." This clause was interpreted after 1917 to mean that a doctor could not
prescribe opiates to an addict, since addiction was not considered a disease. A number of
doctors were arrested and some were imprisoned. The medical profession quickly
learned not to supply opiates to addicts. In United States v. Doremus, 249 U.S. 86 (1919),
the Supreme Court ruled that the Harrison Act was constitutional, and in Webb v. United
States, 249 U.S. 96, 99 (1919) that physicians could not prescribe narcotics solely for
maintenance.[13]
What drugs are likely to be abused?
Cross the Blood Brain Barrier
Cause euphoria
Short onset of action
Short half life
Quick delivery mechanism
Few side effects
Physical Dependence vs. addiction
• Dependence-physiological state
•
•
•
•
Tolerance (need more for same effect)
Withdrawal (sick when no more drug)
Occurs with alcohol, cannabis, opioids, benzodiazepines, nicotine
Does NOT occur with cocaine, amphetamines
• Addiction-compulsive use despite consequences
• Brain disorder due to mismatched reward mechanism
Risk factors
• Biological predisposition toward SA (Family history)
• Genetics
• Psychological-depression and/or trauma/victimization
• Social-family, friends, peers
Critical RISK Factors
• Onset of use before age 15
• Daily or weekly use of one drug
• Poly-drug use
“Youth who make it through the early teen years without substance use
decrease the likelihood of developing the DISORDER by 4 times”
McClellan, Lewis JAMA 2000 PLNDP
Ethanol Pharmacokinetics: Absorption
Rapidly absorbed primarily from stomach
Rate of absorption is variable
blood alcohol conc. depends on:
•
•
•
•
•
Amount and alcohol concentration
Rate of drinking, carbonated
Food consumption and composition
Gastric emptying and gastric metabolism
Hepatic first pass
Alcohol Metabolism
Metabolism
• 90-98% metabolized in liver
Alcohol
Acetate
Acetaldehyde
Alcohol
dehydrogenase
Aldehyde
dehydrogenase
• Alcohol dehydrogenase saturates at low to moderate BACs
(Michaelis-Menten kinetics)
• Apparent zero-order kinetics at moderate BACs
• Alcohol Elimination Rate = 7 g per hr
• Disappearance Rate = 0.015% per hr
Metabolism
Metabolism
• Aldehyde dehydrogenase usually not rate-limiting
• Accumulation of acetaldehyde associated with
headache, gastritis, nausea, dizziness (hangover)
• Aldehyde dehydrogenase inhibition (disulfiram)
Pharmacodynamics: CNS Effects
Alcohol is a CNS depressant
Apparent stimulatory effects result from depression
of inhibitory control mechanisms in the brain
(GABA, Glutamate)
There is a balance between the 2 neurotransmitters.
Characteristic response: euphoria, impaired thought
processes, decreased mechanical efficiency
Prevalence Of Alcohol Use disorder
90% Ever drank
60% Are current drinkers
>40% have temporary problems
10-20% Meet criteria for Abuse
3-10% Meet criteria for Dependence
Genetics Of Alcohol Dependence
Children of Alcohol Dependent parents have 3-4
times increased risk of dependence.
Reduced body sway in response to alcohol in sons
of alcoholics
Natural history of Alcohol Use Disorder
Event
1st drink
1st drunk
1st problem
1st dependence
Death
Age
13
15
18
25-40
60
Alcohol Dependence
• More alcohol for the same effect
• Have withdrawal when stop drinking
• Can be life threating when stopped abruptly
• Three phases of treatment
• Acute withdrawal
• Post withdrawal treatment
• Chronic prevention
Predictors of severity of Alcohol Withdrawal
 Older age
 Severity drinking/tolerance
BAL>250 and pt appears coherent
 Prior AW (“kindling”)
 Major medical/surgical problems
 Sedative/hypnotic use
These are used to determine medical
need for treatment to prevent morbidity
and mortality
Who Needs Inpatient treatment
for Alcohol Withdrawal?
• 10 -20% of patients:
 Previous history of DTs and / or seizures.
 Major medical-Cirrhosis, COPD, CAD
 Major psychiatric and/or drug problems
 Poor support, homelessness
 Pregnancy
Clinical Institute Withdrawal
Assessment (CIWA-Ar)
• Standardized assessment of symptoms
  Autonomic activity (e.g. sweating or pulse
> 100)
 Hand tremor
 Insomnia
 Nausea or vomiting
 hallucinations or illusions
 agitation
 Anxiety
 Grand mal seizures
Withdrawal Therapy
CIWA <10, continue to observe hourly
CIWA 10-20, diazepam 10 mg or lorazepam 1 mg
CIWA >20 diazepam 20 mg or lorazepam 2 mg
Seizure risk highest 18-36 hours after last drink
Delirium Tremens risk highest 72-120 hours after last drink
Consider Haldol 2-5 mg po if psychotic
Low threshold for ICU admission for potentially life
threatening events
Post withdrawal treatment
• Naltrexone can be started
• Acamprosate can be started
• Antidepressants can be started but won’t work right away
• Avoidance of the sedatives is generally recommended
Drugs Approved for treatment of Alcohol
Dependence
• Disulfiram : Aldehyde Dehydrogenase inhibitor
(Antabuse)
• Naltrexone :Reduces craving and modifies
experience of intoxication
• Acamprosate : May reduce negative
reinforcement (Campral)
• Topiramate-Evidence that it increases GABA
which reduces the desire to drink
Disulfiram (Antabuse)
• Alcohol sensitizing
• Deterrent from drinking
• Alters metabolism of ETOH
• Accumulation of acetaldehyde
• No effect on desire
• Can be taken for months to years
• Ingestion within several days
• flushing, throbbing headache, n/v, chest pain,
BP
Naltrexone (ReVia)
• Opioid antagonist
• Blocks opioid receptors (reward system)
• Reducing craving for alcohol
• Reduces the amount of alcohol consumed and
total days of drinking
• Shown to be effective when combined with
physician office visits every few weeks for
reinforcement
Naltrexone IM (Vivitrol)
• Monthly injection
• About $800 a shot
• Better compliance
• Concern about pain as it is a full opioid blocker
Acamprosate
• Glutamate analog
• Available in US as of 2004
• Reduces craving by preventing excitation of glutamate
receptors
• Taken 3 times a day
Topirimate
• Taken once or twice a day
• Has an effect on glutamate receptors in a sub group of people
• Reduced total number of drinking days and reduced amount
consumed
• Can cause dizziness, fatigue and memory problems
• “Among the remedies which it has pleased
Almighty God to give to man to relieve his
sufferings, none is so universal and so
efficacious as opium”
Sydenham, 1680
JRB 2010
• Dopamine pathways in the Ventral Tegmentum(VT) to the Nucleus
Accumbens(NA) and Medial Frontal Cortex(MFC) are activated
during rewarding behaviors. Mu receptors in the VT,NA,MFC,and
Locus Coeruleus(LC). Chronic opiates cause LC inhibition and
stopping them causes excitation in the LC and withdrawal
symptoms. Opiates also reduce glucose metabolism globally in the
brain. GABA receptors are scattered throughout this area and are
involved with reward for ethanol, BZD, and opiates.
JRB 2010
Heroin
Oxycodone
Functional State (Heroin)
Impact of Short-Acting Heroin As Used on a
Chronic Basis in Humans
"High"
"Straight"
"Sick"
Days
JRB 2010
Months
and on and on and on
Modified from Dole, Nyswander and Kreek, 1966
Natural History
• Initial exposure often begins with random, recreational use of pillsoxycodone or hydrocodone combinations by mouth or by sniffing the
crushed pills OR overprescribing by a medical professional
• May remain as a casual use
• Often progresses to need for increased amount for the same effect
(tolerance) and this often leads to Oxycontin use (also crushed and
snorted)
• Once dependence gets established then progresses to heroin and
injection use.
Natural history of heroin use
• Tolerance
• Injection
• Loss of everything- working to maintain habit, burglary, prostitution,
school drop-out rate is much higher.
• This is often a planned economy of starting an unsuspecting teen on
low cost pills, progressing to costly pharmaceuticals and then offering
heroin. Users need to recruit new users.
Opiate effects
• Pain relief as an analgesic
• Drowsiness
• Mood changes
• Mental clouding
• Constipating, nauseating
• Cough suppressant
• Smaller pupils
• Reduce respiration
• Itching
Opiate withdrawal
•
•
•
•
•
•
•
•
•
•
Pain/Dysphoria
Diarrhea
Vomiting
Runny nose and eyes
Dilated pupils
Tremor
Hot and cold feelings
Anxious mood
Aching
Poor sleep
Opioid Withdrawal
• Early: Anxiety, myalgias, mydriasis, rhinorrhea,
lacrimation, yawning
• Mid: fever, chills, sweats, piloerection (cold turkey),
leg muscle cramps (kicking), bone pain, abdominal
cramps
• Late: vomiting, diarrhea, hyperventilation, insomnia
• Withdrawal is very unpleasant but not life
threatening
Opioid Misuse: Medical Complications
• Infections: HIV, Hepatitis B and C, Endocarditis,
meningitis, septicemia, TB, Skin abscess,
phlebitis
• Nephropathy, rhabdomyolysis, PE, lymphedema,
menstrual irregularity
• Impaired immune function
• Hepatic and renal toxicity from acetaminophen
and NSAID use
Opioid Overdose
• Respiratory depression is the cause of death
• Coma, hypoventilation, cyanosis, pinpoint
pupils. Pupils may dilate if cerebral hypoxia
ensues.
• Non-cardiogenic pulmonary edema
• High dose meperidine may cause seizures.
Treatment of Opioid Overdose
• Establish Airway
• Ventilate
• Inject Naloxone. Short ½ life
• Monitor and repeat as needed.
• Beware! You will precipitate withdrawal.
• Treatment for opioid dependence is often
• indicated.
Pharmacological Treatment of Opioid
Dependence
• Short term
Detoxification using non opioids
Detoxification using opioids
• Long term
Opioid agonist treatment
Opioid antagonist
Opioid Detoxification Efficacy
• Extremely high relapse rates ~90%. Sometimes
the same day after leaving facility
• High risk for HIV, Overdose upon relapse
• Must be followed up with structured treatment, 12
step, Recovery Centers
• Abstinence based approach is not the treatment
for Opioid dependence
Opioid Agonist Treatment
• The recommended treatment for Opioid dependence
• Best outcomes, treatment retention and lowest relapse rates.
• Methadone maintenance was the mainstay
• Buprenorphine for office based Rx.
Opioid Agonist Treatment
(OAT)
 Normalizes immune and endocrine
systems, reduce death rates, OD
 Decreases criminal activities
 Decreases illicit opiate use, IVDU,HIV
and Hepatitis C transmission
 Increases pro-social activities,
employment
 Reduces ER visits and hospitalization
Functional State (Heroin)
Impact of Short-Acting Heroin As Used on a
Chronic Basis in Humans
"High"
"Straight"
"Sick"
Days
Months
and on and on and on
Modified from Dole, Nyswander and Kreek, 1966
Heroin
• Enters brain within 30 secs after injecting
• Lasts 30-60 minutes
• After time effects opiate receptor/ endorphin system in brain
stress, sleep, pain
• Stopping it causes physical symptoms within 12 hours and lasting up
to 7 days
• Can permanently change the receptor in the brain causing chronic
anxiety and a state of hyperexcitability
Mortality
Death rate is 50-100 times greater than
general population rate!
Cause of death
22% Accidental, OD
19% Homicide, Suicide, MVA
15% Liver disease
23% Cancer and cardiovascular
Hser, Hoffman, Anglin Arch of Gen Psych 2001
Crime among 491 patients before and
during MMT at 6 programs
Crime Days Per Year
300
250
200
Before TX
During TX
150
100
50
0
A
B
C
D
E
F
Adapted from Ball & Ross - The Effectiveness of Methadone Maintenance
Treatment, 1991
JRB 2010
51
Medication Assisted Treatment
• Both methadone and buprenorphine are “blockers”. They occupy the
opioid receptors in the brain and don’t “allow” shorter acting opioids
to activate the receptors and cause positive effects
• Once stable on a dose, it rarely has to be adjusted
• Allows behavioral changes to be made
MAT
• Methadone is only prescribed and dispensed in an OTP (Opiate
Treatment Program)
• Buprenorphine is prescribed by doctors in an office based opioid
treatment program (OBOT)
• However, in some OTPs buprenorphine is prescribed and dispensed
instead of methadone
Relapse Outcomes in Selected Medical Disorders
100
90
60-80%
80
70
50-60%
60
30-50%
50
40
10-30%
30
20
10
0
Drug/Alcohol Treatment
Diabetes
Hypertension
Percent of clients retreated within 12 months
Asthma(Adult)
Functional State (Heroin)
NOW SIMPLY ADD METHADONE
"High"
"Straight"
"Sick"
and on and on and on
JRB 2010
Very modified, but indebted, to Dole, Nyswander and Kreek, 1966
Methadone
• Methadone, synthetic opioid, created in 1930s in Germany with the
intent to develop an analgesic for wounded soldiers while allied
forces controlled opium exports from the East.
• The drug was undergoing laboratory-based preclinical study. Soon
after World War II, the U.S. military commission had identified this
compound as being of possible therapeutic value and had officially
brought it to the United States for study in the treatment of pain (at
Lexington).
Methadone
• Taken too frequently, or by opioid-naïve patients, methadone will
accumulate and cause sedation or respiratory depression, but once-aday dosing will generally achieve relatively stable blood levels.
• Methadone has high oral bioavailability, reaches peak blood
concentration between 2 and 4 hours after and is relatively lipidsoluble. Less than 3% enters the CSF.
Steady-State Simulation - Maintenance Pharmacotherapy
Attained after 4-5 half-times, 1 dose / half-life
Adapted from
Goodman &
Gilman
Time (multiples of elimination half-lives)
Daily dose remains constant to steady-state
Opioid Agonist Treatment of Addiction - Payte - 1998
Methadone
• Steady state is not attained until methadone is fully distributed and
bound in tissues, and so blood levels continue to rise slowly for 4 to 6
weeks.
• Although patients sometimes complain about drug formulation
changes (tablets versus liquid; differing flavors), there are no
correlated changes in pharmacokinetics or dynamics.
• It can take up to 6 months for most patients to become stabilized and
for heroin use to be significantly reduced and stress hormone levels
to normalize
Side effects
•
•
•
•
Constipation
Weight gain.
Increased perspiration,
Decreased libido and menstrual abnormalities are common during cycles of
heroin use, secondary to disruption of the pulsatile secretion of luteinizing
hormone (LH). Methadone maintenance allows normalization of LH levels.
• Female patients should be advised that they will regain their normal
chance of becoming pregnant as secondary amenorrhea disappears and
normal menstrual cycles with ovulation recommences within 1 year.
Buprenorphine
Partial agonist used for the treatment of opiate dependence in a
doctor’s office
Full agonist
Effect
Partial agonist
Dose
JRB 2010
Buprenorphine
• Subutex®-Buprenorphine only
• Subuxone®-Buprenorphine/Naloxone 4:1 ratio
• Strips and tablets
• Zubsolv®-new formulation
• Both Subutex® and Suboxone® are now generic
• 9.3 million dollars in Medicaid dollars for fiscal year 2013
Buprenorphine
• Was studied in the 1980’s with promise as an alternative to MTD
• Ceiling effect on respiratory depression
• Long half life
• Less reinforcing to addict
• Could expand treatment to 50% of all heroin addicts
• Harrison Act of 1914 was reversed by DATA 2000
• Any waivered MD/DO was eligible to treat
Buprenorphine
• Only MDs or DOs can prescribe
• Have to take an 8 hour training
• Allows one to get a waiver on the DEA license in order to prescribe for
addicts
• Cap of 30 people the first year
• Can apply to lift the cap to 100 after 1 year
• Vt is #1 in the US in number of waivered MDs/DOs and number of
doses of buprenorphine prescribed per capita in the US
Naltrexone
• Full opiate antagonist
• Given in select circumstances
• Doses range 50-100 mg/ day orally or
• Once a month injection (Vivitrol)
• Reducing craving for alcohol
• S/E’s: depression, nausea, GI upset, HA, drowsiness, serious effects on
liver
Narcan
• Reverses opioid overdose with one dose
• Is added to Buprenorphine to make Suboxone
• If injected, kicks all opioids from the brain and precipitates
withdrawal.
• Can be given as a shot or as a nasal spray
• Works within minutes
• Wide variation in availability around VT
Hub and Spoke
• Idea was to have methadone clinics also prescribe buprenorphine and
take more difficult patients and keep they from being discharged from
OBOT (HUBS)
• Once stable, some on buprenorphine could go back to OBOT
(SPOKES)
• OBOT could enroll new people knowing there was a back up if the
patients relapsed
• 5 Hubs and >30 Spokes around the state
• 1 FTE nurse and case manager in the Spokes to provide services based
on Blueprint for Health waiver in the State Chronic Care Initiative
Impaired Driving
• Methadone maintained people can’t hold a Commercial Driver’s
License
• No restriction for buprenorphine
• Mixed with other drugs can lead to sedation, especially
benzodiazepines, muscle relaxants, sleep aids
• We monitor as best we can once started in treatment and get
informed consent about sedation